advisory re columnist Millet Mananquil and Johnson and Johnson, Inc.which was identified as the local source of: Johnson' s Pure Essentials, Modess and
Carefree, Band-Aid brand of adhesive bandages, Life-Scan glucose monitoring systems, Neutrogena facial, body and hair care products for adults, Ethicon
sutures. Said Millet Mananquil made public claims regarding a Neutrogena product. There is evidence that said corporation received my request for
information regarding said claims by said Mananquil regarding said product. I received a letter dated May 19, 2009 and bearing the name of said corporation
and the name "Michell F. Frondozo - Customer Service Specialist" as the sender of said letter. Said letter from Johnson and Johnson, Inc. did not support
said claims by said Mananquil regarding Neutrogena product. There is evidence that a representative of the Department of Trade and Industry Bureau of
Trade Regulation and Consumer Protection accepted my complaint vs. said corporation.

evidence vs. Mandaluyong Vice-Mayor
I believe said vice-mayor violated R.A. 6713. There is evidence that sometime between March 20, 2009 and April 13, 2009, said vice-mayor, or his agent, received my registered letter addressed to said vice-mayor and dated March 19, 2009.
Said letter was a customer advisory vs. SM Megamall, Abenson, Power Nut Store and Domini M. Torrevillas. I received back on April 14, 2009, the registry
return receipt for said letter, which was designated as registered letter No. 8833. Up to July 3, 2009, said mayor has not provided me with a reply to said
letter.

web sites with useful free information:

CDC Features _ Men's Health
http://www.cdc.gov/Features/HealthyMen/

Men can take daily steps to live a safer and healthier life, prevent disease and disability, and protect themselves.



Men can be safer, stronger, and healthier at work, home, and play by taking daily steps and getting care when needed. Improving men's health is not limited to the doctor's office or hospital. Improving men's health starts at home with individuals and families taking steps to live safer and healthier lives.

Current Features

* Cancer and Men
* Disparities & Youth
* Elder Abuse
* H1N1 Flu (Swine Flu)
* Men's Health
* Muscular Dystrophy
* Sickle Cell
* Features Index
* Features by Date

Be Informed About Your Health
Learn your family health history.

Are there any new conditions or diseases that have occurred in your close relatives since your last visit? If so, let your doctor or nurse know. Family history might influence your risk of developing heart disease, stroke, diabetes, or cancer. Your doctor or nurse will assess your risk of disease based on your family history and other factors. He or she may also recommend things you can do to help prevent disease, such as exercising more, changing your diet, or using screening tests to help detect disease early.

Using Family History to Promote Health
http://www.cdc.gov/genomics/public/famhist.htm

Fact Sheets & Brochures
Family History is Important for Health

* English: Link here to download free Adobe Reader Fact Sheet (69KB) | globe icon Web Version | Link here to download free Adobe Reader Brochure (627KB)
* Spanish: pdf icon Fact Sheet (64KB) | globe icon Web Version

Does Diabetes Run in Your Family?

* English: Link here to download free Adobe Reader Brochure (1.81MB)
* Spanish: pdf icon Brochure (1.7MB)



http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116849.htm
FDA NEWS RELEASE

FOR IMMEDIATE RELEASE
February 1, 2008


Media Inquiries:
Susan Cruzan, 301-827-6242
Rita Chappelle, 301-827-6242
Consumer Inquiries:
888-INFO-FDA

FDA Issues Public Health Advisory on Chantix
Agency requests that manufacturer add new safety warnings for smoking cessation drug

The U.S. Food and Drug Administration (FDA) today issued a Public Health Advisory to alert health care providers, patients, and caregivers to new safety warnings concerning Chantix (varenicline), a prescription medication used to help patients stop smoking.

On Nov. 20, 2007, FDA issued an Early Communication to the public and health care providers that the agency was evaluating postmarketing adverse event reports on Chantix related to changes in behavior, agitation, depressed mood, suicidal ideation, and actual suicidal behavior.

As the agency's review of the adverse event reports proceeds, it appears increasingly likely that there may be an association between Chantix and serious neuropsychiatric symptoms. As a result, FDA has requested that Pfizer, the manufacturer of Chantix, elevate the prominence of this safety information to the warnings and precautions section of the Chantix prescribing information, or labeling. In addition, FDA is working with Pfizer to finalize a Medication Guide for patients. This is an example of FDA working with drug manufacturers throughout products' lifecycles to keep health care professionals and patients informed of new and emerging safety data.

"Chantix has proven to be effective in smokers motivated to quit, but patients and health care professionals need the latest safety information to make an informed decision regarding whether or not to use this product," said Bob Rappaport, M.D., director of the FDA's Division of Anesthesia, Analgesia and Rheumatology Products. "While Chantix has demonstrated clear evidence of efficacy, it is important to consider these safety concerns and alert the public about these risks. Patients should talk with their doctors about this new information and whether Chantix is the right drug for them, and health care professionals should closely monitor patients for behavior and mood changes if they are taking this drug."

Chantix was approved by FDA in May 2006 as a smoking cessation drug. Chantix acts at sites in the brain affected by nicotine and may help those who wish to stop smoking by providing some nicotine effects to ease the withdrawal symptoms and by blocking the effects of nicotine from cigarettes if users resume smoking.

In the Public Health Advisory and a Health Care Professional Sheet that was also issued today, FDA emphasized the following safety information for patients, caregivers, and health care professionals:

* Patients should tell their health care provider about any history of psychiatric illness prior to starting Chantix. Chantix may cause worsening of current psychiatric illness even if it is currently under control. It may also cause an old psychiatric illness to reoccur. FDA notes that patients with these illnesses were not included in the studies conducted for the drug's approval.
* Health care professionals, patients, patients' families, and caregivers should be alert to and monitor for changes in mood and behavior in patients treated with Chantix. Symptoms may include anxiety, nervousness, tension, depressed mood, unusual behaviors and thinking about or attempting suicide. In most cases, neuropsychiatric symptoms developed during Chantix treatment, but in others, symptoms developed following withdrawal of varenicline therapy.
* Patients should immediately report changes in mood and behavior to their doctor.
* Vivid, unusual, or strange dreams may occur while taking Chantix.
* Patients taking Chantix may experience impairment of the ability to drive or operate heavy machinery.

FDA will continue to update health care professionals with new information from FDA's continuing review or if new information is received on Chantix and serious neuropsychiatric symptoms. FDA may consider requesting further revisions to the labeling or taking other regulatory action as the agency's continuing reviews and conclusions warrant.

For more information:
http://www.fda.gov/cder/drug/infopage/varenicline/default.htm


Page Last Updated: 06/18/2009

Advisory re Sonca brand flashlights
which have been sold in the Philippines. The following was on the web site of what was identified as the U.S. government web site Consumer Product Safety Commission:

"CPSC & Sonca Products Recall Toy Flashlights
http://www.cpsc.gov/cpscpub/prerel/prhtml99/99172a.html

NEWS from CPSC
U.S. Consumer Product Safety Commission
Office of Information and Public Affairs Washington, DC 20207
FOR IMMEDIATE RELEASE
September 22, 1999
Release # 99-172a Company Phone Number: (800) 669-6394
CPSC Consumer Hotline: (800) 638-2772
CPSC Media Contact: Kim Dulic, (301) 504-7058
CPSC & Sonca Products Recall Toy Flashlights
PRODUCT: Toy flashlights - Sonca Products Ltd., of Hong Kong, is voluntarily recalling about 5,500 toy flashlights. The flashlight came with Playmobil's Coastal Search and Rescue Boats toy set (item 3063), which included a rescue boat, rescue raft, diver, and captain among other diving equipment. The toy set is not part of the recall, only the flashlight. The flashlights are made of blue rubber, measure about 6.25 inches long, and have a black cord attached. The flashlight operates with two "AA" batteries. The word "PLAYMOBIL" is on the side of the flashlight. Independent toy stores nationwide sold the toy set containing the recalled flashlight from July 1999 to September 1999 for about $40.

PROBLEM: The spring in the flashlight's battery compartment can dislodge, causing the batteries to overheat or leak. Children can suffer burns from the leaking battery.

INCIDENTS/INJURIES: Sonca has received four reports from Europe of batteries overheating or leaking. There have been two reports of minor property damage and two minor injuries, including eye irritation and skin burns.

WHAT TO DO: Consumers should take the flashlight away from children immediately. Consumers should call Sonca at (800) 669-6394 between 7 a.m. and 7 p.m. CT Monday through Friday for instructions on returning the flashlight for a $5 refund. Consumers also can access the company's web site at www.sonca.com."


web site with useful, free information:

recalls org web site
http://recalls.org/

safetyandchildren web site
http://www.safetyandchildren.com/


ice cat web site
http://www.icecat.biz/

kidsindanger org web site
http://www.kidsindanger.org/


http://www.apma.org/
American Podiatric Medical Association